Matson et al. [132] conducted studies on 42 metastatic melanoma patients treated with anti-PD-1 antibodies (n = 38) and anti-CTLA-4 antibodies (n = 4; results obtained for this cohort did not moderate general findings), among who 16 patients were responders and 26 patients were non-responders. This evidence concerns the gene CTLA4 and metastatic melanoma.